This is a working overview of Phase 3 trial, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-30 and is reviewed periodically as new material appears.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Requires reconstitution before use |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Storage, powder | 2 to 8 degrees Celsius | Protect from light and moisture |
| Storage, solution | Refrigerated, short term | Use promptly after reconstitution |
| Common assays | Reversed-phase HPLC and mass spectrometry | Purity and identity respectively |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Transfer ribonucleic acid (tRNA), formerly referred to as soluble ribonucleic acid (sRNA), is an adaptor molecule composed of RNA, typically 76 to 90 nucleotides in length (in eukaryotes). In a cell, it provides the physical link between the genetic code in messenger RNA (mRNA) and the amino acid sequence of proteins, carrying the correct sequence of amino acids to be combined by the protein-synthesizing machinery, the ribosome. Each three-nucleotide codon in mRNA is complemented by a three-nucleotide anticodon in tRNA. As such, tRNAs are a necessary component of translation, the biological synthesis of new proteins in accordance with the genetic code.
=== UFC merged with WWE to form TKO Group === In April 2023, Endeavor Group Holdings announced that UFC would merge with the wrestling promotion WWE to form TKO Group Holdings, a new Public company majority-owned by Endeavor, with Vince McMahon serving as an executive chairman of the new entity and White remaining as UFC president. The merger was completed on September 12, 2023.
Carefully designing the sequences of the staple strands enables scientists to precisely direct the scaffold strand's folding into a predetermined shape with high precision. On a chemical level, the hydrogen bonds that exist between the complementary base pairs provide strength and stability to the folded DNA origami structures. Additionally, DNA is a relatively stable molecule, offering resilience in physiological conditions. One of the advantages of using a DNA origami nanostructure over an otherwise classified DNA nanostructure is the ease of defining finite structures. In the design of some other DNA nanostructures, it can be impractical to design an extremely large number of individualized strands if the entire structure is composed of smaller strands. One method of bypassing the need for a huge number of different strands is to use repeating units, which comes with the disadvantage of a distribution of sizes and sometimes shapes. DNA Origami, however, forms discrete structures. Applications for DNA origami are primarily focused around the ability to exert fine control on systems, especially by constraining positions of molecules, typically by attachment to the DNA origami nanostructures. Current applications are primarily focused on sensing and drug delivery, but many additional applications have been investigated.
== Further reading == John Bankston, Francis Crick and James D. Watson; Francis Crick and James Watson: Pioneers in DNA Research (Mitchell Lane Publishers, Inc., 2002) ISBN 1-58415-122-6. Bill Bryson; A Short History of Nearly Everything (Broadway Books, 2003) ISBN 0-7679-0817-1. Soraya De Chadarevian; Designs For Life: Molecular Biology After World War II, CUP 2002, 444 pp; ISBN 0-521-57078-6. Roderick Braithwaite. Strikingly Alive: The History of the Mill Hill School Foundation 1807–2007; published Phillimore & Co. ISBN 978-1-86077-330-3 Edwin Chargaff; Heraclitean Fire, Rockefeller Press, 1978. S. Chomet (Ed.), D.N.A. Genesis of a Discovery, 1994, Newman- Hemisphere Press, London Dickerson, Richard E.; Present at the Flood: How Structural Molecular Biology Came About, Sinauer, 2005; ISBN 0-87893-168-6. Edward Edelson, Francis Crick And James Watson: And the Building Blocks of Life, Oxford University Press, 2000, ISBN 0-19-513971-2. John Finch; A Nobel Fellow On Every Floor, Medical Research Council 2008, 381 pp, ISBN 978-1-84046-940-0. Hager, Thomas; Force of Nature: The Life of Linus Pauling, Simon & Schuster 1995; ISBN 0-684-80909-5 Graeme Hunter; Light Is A Messenger, the life and science of William Lawrence Bragg (Oxford University Press, 2004) ISBN 0-19-852921-X. Horace Freeland Judson, The Eighth Day of Creation. Makers of the Revolution in Biology; Penguin Books 1995, first published by Jonathan Cape, 1977; ISBN 0-14-017800-7. Errol C. Friedberg; Sydney Brenner: A Biography, pub. CSHL Press October 2010, ISBN 0-87969-947-7.
Rectocele. Anterior rectocele is present in about 70% of cases of IRP. Enterocele may herniate into an IRP. Solitary rectal ulcer syndrome. Dyssynergic defecation / anismus. Descending perineum syndrome. Chronic anal fissure. Hemorrhoids. In female patients, prolapse of the posterior compartment of the pelvis rarely occurs without abnormalities of the middle or anterior compartments.
Sources: en.wikipedia.org
The mechanism of action of biguanides is not fully understood, and many mechanisms have been proposed for metformin. Biguanides do not affect the output of insulin, unlike other hypoglycemic agents such as sulfonylureas and meglitinides. Therefore, they are effective in Type 2 diabetics; and in Type 1 diabetes when used in conjunction with insulin therapy. Mainly used in Type II diabetes, metformin is considered to increase insulin sensitivity in vivo, resulting in reduced plasma glucose concentrations, increased glucose uptake, and decreased gluconeogenesis. However, in hyperinsulinemia, biguanides can lower fasting levels of insulin in plasma. Their therapeutic uses derive from their tendency to reduce gluconeogenesis in the liver, and, as a result, reduce the level of glucose in the blood. Biguanides also tend to make the cells of the body more willing to absorb glucose already present in the bloodstream, and there again reducing the level of glucose in the plasma. Biguanides have been shown to interact with copper, specifically in mitochondria, where they interfere with cell metabolism by chelating Copper in its 2+ oxidation state (Cu(II)).
The temporarily high level of 135Xe with its high neutron absorption cross-section makes it difficult to restart the reactor for several hours. The neutron-absorbing 135Xe acts like a control rod, reducing reactivity. The inability of a reactor to be started due to the effects of 135Xe is sometimes referred to as xenon-precluded start-up, and the reactor is said to be "poisoned out". The period of time that the reactor is unable to overcome the effects of 135Xe is called the "xenon dead time". If sufficient reactivity control authority is available, the reactor can be restarted, but the xenon burn-out transient must be carefully managed. As the control rods are extracted and criticality is reached, neutron flux increases many orders of magnitude and the 135Xe begins to absorb neutrons and be transmuted to 136Xe. The reactor burns off the nuclear poison. As this happens, the reactivity and neutron flux increases, and the control rods must be gradually reinserted to counter the loss of neutron absorption by the 135Xe. Otherwise, the reactor neutron flux will continue to increase, burning off even more xenon poison, on a path to runaway criticality. The time constant for this burn-off transient depends on the reactor design, power level history of the reactor for the past several days, and the new power setting. For a typical step up from 50% power to 100% power, 135Xe concentration falls for about 3 hours.
The Senedd Commissioner for Standards finds that Senedd member Siân Gwenllian breached the Senedd's code of conduct after sharing a confidential letter, but recommends no further action is taken against her. 25 April – The electoral officer of North Kesteven District Council rules that Andrea Jenkyns is entitled to stand in the 2025 Lincolnshire mayoral election after questions were raised about her eligibility because she is not on the Lincolnshire electoral register, a prerequisite for standing. 28 April – Martin Dowey temporarily stands down as leader of South Ayrshire Council over a secret recording in which he appears to suggest he can help award contracts to "pals". 29 April – Scottish Greens MSP Maggie Chapman survives an attempt to remove her from the Scottish Parliament's equalities committee following her criticism of the judiciary over the Supreme Court's ruling on biological sex. 30 April – The Parliamentary Commissioner on Standards launches an investigation into Chancellor Rachel Reeves' failure to declare receiving theatre tickets within the required time that MPs must declare gifts.
Animation – The Last of Us Part II Artistic Achievement – Hades Audio Achievement – Ghost of Tsushima Best Game – Hades British Game – Sackboy: A Big Adventure Debut Game – Carrion EE Game of the Year – The Last of Us Part II Evolving Game – Sea of Thieves Family – Sackboy: A Big Adventure Game Beyond Entertainment – Animal Crossing: New Horizons Game Design – Hades Multiplayer – Animal Crossing: New Horizons Music – Spider-Man: Miles Morales Narrative – Hades Original Property – Kentucky Route Zero: TV Edition Performer in a Leading Role – Laura Bailey as Abby in The Last of Us Part II Performer in a Supporting Role – Logan Cunningham for multiple roles in Hades Technical Achievement – Dreams BAFTA Fellowship – Siobhan Reddy
== Clinical significance == Urothelium is susceptible to carcinoma. Because the bladder is in contact with urine for extended periods, chemicals that become concentrated in the urine can cause bladder cancer. For example, cigarette smoking leads to the concentration of carcinogens in the urine and is a leading cause of bladder cancer. Aristolochic acid, a compound found in plants of the family Aristolochiaceae, also causes DNA mutations and is a cause of liver, urothelial and bladder cancers. Occupational exposure to certain chemicals is also a risk factor for bladder cancer. This can include aromatic amines (aniline dye), polycyclic aromatic hydrocarbons, and diesel engine exhaust.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.
Mass spectrometry gives the observed mass, which is compared against the value calculated from the sequence. Peptide mapping after digestion provides a second, sequence-level check. Chromatographic retention alone is not sufficient for identity.
Antibodies raised against one GHRH-related peptide may bind other members of the same family. That cross-reactivity inflates or distorts measured concentrations. Assay validation with defined standards is therefore necessary before results are interpreted.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.